EGFR wild-type
|
NSCLC
|
EGFR wild-type
|
NSCLC
|
durvalumab Sensitive: B - Late Trials
|
durvalumab Sensitive: B - Late Trials
|
EGFR wild-type
|
LUAD
|
EGFR wild-type
|
LUAD
|
rivoceranib Sensitive: C2 – Inclusion Criteria
|
rivoceranib Sensitive: C2 – Inclusion Criteria
|
EGFR wild-type
|
NSCLC
|
EGFR wild-type
|
NSCLC
|
rivoceranib Sensitive: C2 – Inclusion Criteria
|
rivoceranib Sensitive: C2 – Inclusion Criteria
|
EGFR wild-type
|
NSCLC
|
EGFR wild-type
|
NSCLC
|
erlotinib Sensitive: C2 – Inclusion Criteria
|
erlotinib Sensitive: C2 – Inclusion Criteria
|
EGFR wild-type
|
NSCLC
|
EGFR wild-type
|
NSCLC
|
atezolizumab Sensitive: C2 – Inclusion Criteria
|
atezolizumab Sensitive: C2 – Inclusion Criteria
|
EGFR wild-type
|
NSCLC
|
EGFR wild-type
|
NSCLC
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
pembrolizumab Sensitive: C2 – Inclusion Criteria
|
EGFR wild-type
|
NSCLC
|
EGFR wild-type
|
NSCLC
|
nivolumab Sensitive: C2 – Inclusion Criteria
|
nivolumab Sensitive: C2 – Inclusion Criteria
|
EGFR wild-type
|
NSCLC
|
EGFR wild-type
|
NSCLC
|
pemetrexed Sensitive: C3 – Early Trials
|
pemetrexed Sensitive: C3 – Early Trials
|
EGFR wild-type
|
NSCLC
|
EGFR wild-type
|
NSCLC
|
cabozantinib tablet Sensitive: C3 – Early Trials
|
cabozantinib tablet Sensitive: C3 – Early Trials
|
EGFR wild-type
|
NSCLC
|
EGFR wild-type
|
NSCLC
|
erlotinib + cabozantinib tablet Sensitive: C3 – Early Trials
|
erlotinib + cabozantinib tablet Sensitive: C3 – Early Trials
|
EGFR wild-type
|
Lung Non-Squamous Non-Small Cell Cancer
|
EGFR wild-type
|
Lung Non-Squamous Non-Small Cell Cancer
|
tislelizumab Sensitive: C3 – Early Trials
|
tislelizumab Sensitive: C3 – Early Trials
|
EGFR wild-type
|
NSCLC
|
EGFR wild-type
|
NSCLC
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
PD1 inhibitor Sensitive: C3 – Early Trials
|
EGFR wild-type
|
LUAD
|
EGFR wild-type
|
LUAD
|
REC-4881 Sensitive: D – Preclinical
|
REC-4881 Sensitive: D – Preclinical
|
EGFR wild-type
|
LUAD
|
EGFR wild-type
|
LUAD
|
AZD8330 Sensitive: D – Preclinical
|
AZD8330 Sensitive: D – Preclinical
|
EGFR wild-type
|
LUAD
|
EGFR wild-type
|
LUAD
|
PF-04691502 Sensitive: D – Preclinical
|
PF-04691502 Sensitive: D – Preclinical
|
EGFR wild-type
|
LUAD
|
EGFR wild-type
|
LUAD
|
GSK2126458 Sensitive: D – Preclinical
|
GSK2126458 Sensitive: D – Preclinical
|
EGFR wild-type
|
NSCLC
|
EGFR wild-type
|
NSCLC
|
RTB101 Sensitive: D – Preclinical
|
RTB101 Sensitive: D – Preclinical
|
EGFR wild-type
|
NSCLC
|
EGFR wild-type
|
NSCLC
|
gefitinib Sensitive: D – Preclinical
|
gefitinib Sensitive: D – Preclinical
|